2024 March Chinese E-cigarette Export Data to Australia Analysis

Industry Insight by 2FIRSTS
May.10.2024
2024 March Chinese E-cigarette Export Data to Australia Analysis
China's e-cigarette exports to Australia in March 2024 dropped significantly, with a total value of $1.14 million.

According to the latest trade data released by the General Administration of Customs, 2FIRSTS has compiled the e-cigarette export figures from China to Australia for March 2024. The specifics are as follows:

 


3月中国出口澳大利亚电子烟约114万美元 环比下降55.35%

 

The export revenue was approximately $1.14 million, a decrease of 55.35% month-on-month and a decrease of 96.58% year-on-year.


3月中国出口澳大利亚电子烟约114万美元 环比下降55.35%

The export volume is approximately 28 tons, which is a decrease of 43.34% compared to the previous period and a decrease of 95.59% compared to the same period last year.

 


3月中国出口澳大利亚电子烟约114万美元 环比下降55.35%

 

The export unit price is $40.81 per kilogram, a decrease of 21.19% compared to the previous period and a decrease of 22.60% year-on-year. The average price for "e-cigarettes and similar personal electronic vaporizing devices" is $1.14 per unit.

 

 

Among them, "e-cigarettes and similar personal electronic vaporizing devices" account for 20.85% of the export product category, while "non-tobacco or non-reconstituted tobacco products containing nicotine for non-combustible use" account for 79.15%.

 

2024 March Chinese E-cigarette Export Data to Australia Analysis

 

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Experts Make the Case for THR in Asia-Pacific, as Demand, Science, and Industry Drive Its Growth
Experts Make the Case for THR in Asia-Pacific, as Demand, Science, and Industry Drive Its Growth
At the inaugural AFN, Dr. Rohan Sequeira and Dr. Alex Wodak emphasized that THR offers a science-based approach to reduce smoking-related harm—not merely as an alternative to cessation. They urged policymakers across Asia to reassess tobacco control and include non-combustible products in public health strategies. This article outlines the scientific foundation of THR, its regional challenges, and growth momentum.2Firsts provided in-depth coverage of the forum.
Sep.09
Japan Tobacco’s Greece Subsidiary Posts $900 Million Revenue in 2024, Plans to Boost Ploom Market Expansion
Japan Tobacco’s Greece Subsidiary Posts $900 Million Revenue in 2024, Plans to Boost Ploom Market Expansion
Japan Tobacco International’s (JTI) Greece operations are projected to generate over €800 million (approximately $900 million) in revenue in 2024, with a net profit of €958,000 (about $1.11 million), marking a growth in market share despite challenging conditions. JTI’s innovation is driving market expansion in Greece, with its Ploom products successfully entering the market.
Jul.18 by 2FIRSTS.ai
Brazilian city council of Anápolis approves new law banning the use of e-cigarettes and hookahs in public places
Brazilian city council of Anápolis approves new law banning the use of e-cigarettes and hookahs in public places
Anápolis city council approves ban on e-cigarettes and hookah in public places, awaiting Mayor Márcio Corrêa's signature.
Aug.13 by 2FIRSTS.ai
Juul Labs Files Lawsuit Against NJOY and Altria Over Patent Infringement
Juul Labs Files Lawsuit Against NJOY and Altria Over Patent Infringement
Juul Labs sues NJOY and Altria for patent infringement, escalating legal battle over e-cigarette technology.
Aug.11 by 2FIRSTS.ai
Experts Make the Case for THR in Asia-Pacific, as Demand, Science, and Industry Drive Its Growth
Experts Make the Case for THR in Asia-Pacific, as Demand, Science, and Industry Drive Its Growth
At the inaugural AFN, Dr. Rohan Sequeira and Dr. Alex Wodak emphasized that THR offers a science-based approach to reduce smoking-related harm—not merely as an alternative to cessation. They urged policymakers across Asia to reassess tobacco control and include non-combustible products in public health strategies. This article outlines the scientific foundation of THR, its regional challenges, and growth momentum.2Firsts provided in-depth coverage of the forum.
Sep.09
WHO Criticized for Questioning FDA’s Harm Reduction Assessment, Accused of Defying Scientific Consensus
WHO Criticized for Questioning FDA’s Harm Reduction Assessment, Accused of Defying Scientific Consensus
A World Health Organization (WHO) official, Dr. Roa, recently questioned the U.S. Food and Drug Administration’s (FDA) scientific assessment of e-cigarettes and nicotine pouches, claiming there was no independent consensus and suggesting its conclusions may have been influenced by the industry. Her remarks contradict the consensus of leading international scientific bodies and are seen as a direct challenge to FDA’s credibility and to the integrity of public health science.
Aug.20 by 2FIRSTS.ai